echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Hydrogel-assisted CAR-T therapy is effective in treating eye cancer

    Hydrogel-assisted CAR-T therapy is effective in treating eye cancer

    • Last Update: 2020-11-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    A new study published in Nature Cancer by researchers at the University of North Carolina's Lineberger Comprehensive Cancer Center found that CAR-T cells targeting neuroglycoside GD2 successfully eliminated retinal styrooma cells without damaging the eyesight of mice when combined with local releases of IL-15 and injectable hydrogels.
    source: Nature Cancer Retinoblastoma (RB) is a rare malignant tumor that occurs in infants under 3 years of age and is caused by mutations in the double allied gene of the retinoblastoma gene (RB1).
    that although the cancer can be cured in a timely manner at an early stage, about 5% of cases can still lose vision.
    clinical needs for effective treatment of tumors and the ability to maintain vision in children have not been met.
    GD2 is expressed in human retinal syringe tumors, but this substance is not expressed in normal human retina (below).
    Although GD2 CAR-T has good tolerance and clinical benefits in some neuroblastoma patients (neuroblastoma is an embryonic tumor that can develop rapidly and has certain genetic characteristics of retinal scleoma), it is not clear whether targeting GD2 can safely eliminate intraocular tumors.
    Source: Nature Cancer To test the safety and benefits of targeting GD2, researchers injected GD2 CAR-T into the retina of a mouse model of a retinal symacyte heterogeneous transplant, showing that tumor development was delayed but failed to eliminate the tumor.
    the researchers then built CAR-T cells that secrete IL-15, a cytokine that enhances T-cell proliferation, activation, and survival.
    results showed that adding IL-15 did not cause retinal scleroblastoma in mice treated with CD19 CAR-T to subside, but GD2 CAR-T, which expressed IL-15, had significantly improved anti-tumor effects, with 60 percent of the treated mice remaining tumor-free until the 70th day.
    GD2. CAR.15 Anti-tumor effects were significantly enhanced (Source: Nature Cancer) In order to enhance the durability of CAR-T cells in tumors, the researchers chose the shell polysaccharine-polyglycol (PEG) thermal hydrogel as the best injectable hydrogel to deliver CAR-T in the eye.
    T cells encapsulated in hydrogels remain active, released from the gel inside and out within 1 week, and retain cytotoxicity.
    This hydrogel can significantly improve the anti-tumor effect of GD2 CAR-T, after injecting hydrogel containing CAR-T cells containing IL-15 into the retina of mice, not only can fully control tumor growth and prevent tumor recurrence, but also improve the structural recovery of the retina.
    injectable hydrogels can further improve the treatment of GD2 CAR.15-T and prevent tumor recurrence (Source: Nature Cancer) This gel encapsulation therapy is currently being clinically tested in children with neuroblastoma. Professor Barbara Savoldo,
    co-author of the paper, said: "We hope to be able to test the safety of gel injections in clinical trials in children's retinal scleroblastoma and, if safe, to continue to study the effects of this method on tumor reduction or elimination.
    " References: 1, Wang, K., Chen, Y., Ahn, S. et al. GD2-specific CAR T cells encapsulated in an injectable hydrogel control retinoblastoma and preserve vision. Nature Cancer (2020) 2 s Dimaras, H., Corson, T., Cobrinik, D. et al. Retinoblastoma. Nature Reviews Disease Primers (2015) 3 s therapy using immune system cells preserves in mice implanted with rare eye cancer (Source: UNC Lineberger)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.